{'fraction_non_alphanumeric': 0.0375, 'fraction_numerical': 0.006818181818181818, 'mean_word_length': 5.204225352112676, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Preliminary study on early fibrosis of chronic hepatitis B treated with Ginkgo biloba Composita].

The purpose of this paper was to study the effect of Ginkgo biloba Composita (GBC) on liver collagen fibrosis. The 86 patients were suffering from chronic persistent and active hepatitis B with early fibrosis confirmed by liver biopsy. Serum pro-collagen-III-peptide (PIIIP), laminin (LN), superoxide dismutase (SOD), malonyldialdehyde (MDA) were determined and some patients' biopsies examined with light and electron microscope before and after treatment were observed. By the end of 3 months, the results showed that PIIIP, LN, SOD, MDA were significantly decreased after GBC treatment (P < 0.01) and liver fibrosis of patients was partly reabsorbed and had remission. It was suggested that GBC was effective in arresting the development of liver fibrosis of chronic hepatitis.